Smith & Nephew plc vs Vanguard International High Dividend Yield ETF — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Vanguard International High Dividend Yield ETF trades at $105.38. The key difference: Smith & Nephew plc pays a 2.85% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | VYMI | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $38.53 | $107.13 |
52-Week Low | $27.80 | $82.92 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
VYMI trades at $106.20, down 0.78% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF has gained attention for its international high-dividend yield strategy, recently hitting a 52-week high near current levels. Recent news highlights its outperformance versus domestic dividend ETFs and growing institutional interest.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's strong dividend growth. Key risks include currency fluctuations and global economic volatility. With technical support at $105-106 and resistance at $107-108, the ETF offers income-focused exposure to international equities.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →